News Headlines
-
Ipsen And Sutro Biopharma Announce Exclusive Global Licensing Agreement For An ADC Targeting Solid Tumors
4/2/2024
Ipsen and Sutro Biopharma today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.1
-
Blue Wolf Capital To Acquire OSD CDMO Sites From Recipharm
4/2/2024
Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, announced today that it has committed, subject to regulatory clearances, to acquire seven manufacturing and development facilities: Solna, Stängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, from Recipharm, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.
-
BioInvent Announces A New Clinical Trial Collaboration And Supply Agreement With MSD To Evaluate BI-1910, The Company’s Second Anti-TNFR2 Antibody In Combination With KEYTRUDA (pembrolizumab)
4/2/2024
BioInvent International AB (“BioInvent”) a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA (pembrolizumab).
-
Invenra Inc. Announces A Strategic Collaboration With Catalent To Co-Discover Novel Bispecific ADCs
4/2/2024
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.
-
Delpharm Continues Its Growth In Europe With The Acquisition Of State-Of-The-Art Drug Production Facilities In The Netherlands, From Astellas
4/2/2024
The site, fully equipped with state-of-the-art technologies, is located in the Netherlands in a 31,600 square meter unit created in 1994.
-
Aterian Investment Partners To Recapitalize CPL, A Leading Pharmaceutical Contract Development And Manufacturing Organization
4/1/2024
Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
-
Bora Pharmaceuticals Completes The Acquisition Of Upsher-Smith
4/1/2024
Bora Pharmaceuticals Co., Ltd. today announced that it has successfully completed the acquisition of Upsher-Smith Laboratories, LLC (“Upsher-Smith”), a generics manufacturer and marketer based in Minnesota, U.S., from its sellers, Sawai Group Holdings and Sumitomo Corporation of Americas.
-
Intravacc And Primrose Bio Announce Partnership To Enhance Conjugate Vaccine Development
3/28/2024
Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, announced a strategic partnership to enhance the development and supply of conjugate vaccines.
-
Astellas Breaks Ground On New €330M State-Of-The-Art Facility In Tralee, Co. Kerry, Ireland
3/27/2024
Today, Astellas Ireland Co., Ltd, a wholly owned subsidiary of Astellas Pharma Inc., held a ceremony to mark the breaking of the ground and start of construction for its new €330M, state-of-the-art facility at Kerry Technology Park, Tralee, Co. Kerry.
-
Aragen Operationalizes First Phase Of Its Biologics Manufacturing Facility In India
3/27/2024
Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, announced that it has operationalized the first phase of its biologics manufacturing facility in Bangalore, India through its 100% subsidiary, Aragen Biologics Pvt Ltd.